Heqet Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Heqet Therapeutics is an early-stage Italian biotech pioneering a novel approach to cardiac regeneration following myocardial infarction (MI). Its core technology involves the upregulation of specific non-coding RNAs, primarily microRNAs (miRNAs), to stimulate cardiomyocyte proliferation and repair damaged heart tissue, targeting pathways like Hippo and actin cytoskeleton regulation. Founded on strong academic research with multiple key publications, including promising large animal (pig) data, the company is positioned to tackle the significant unmet need of preventing heart failure post-MI. As a private, pre-clinical, and pre-revenue entity, its near-term focus is advancing its lead programs through development.

CardiovascularAcute Myocardial Infarction

Technology Platform

Non-coding RNA (microRNA) based platform targeting multiple pathways (Hippo, cytoskeletal) to induce cardiomyocyte proliferation and cardiac regeneration.

Opportunities

The global market for heart failure therapies is massive and growing, with a high unmet need for treatments that repair heart damage rather than just manage symptoms.

Success in clinical trials could position Heqet's one-time regenerative therapy as a new standard of care post-MI, offering blockbuster potential.

The platform technology could also be expanded to other regenerative medicine indications.

Risk Factors

The technology faces significant translational risks moving from large animal models to humans, including delivery challenges and long-term safety concerns of inducing cell proliferation.

As a pre-revenue, early-stage company, it is highly dependent on securing substantial funding.

It also faces regulatory uncertainty as a first-in-class regenerative therapy and potential competition from other emerging modalities.

Competitive Landscape

The field of cardiac regeneration is nascent but includes approaches like stem/progenitor cell therapies, gene therapies using other factors (e.g., FGF, VEGF), and small molecules. Heqet's miRNA-based, multi-target approach is a key differentiator. While few direct competitors are in late stages, larger pharmaceutical companies with cardiovascular expertise could enter the space rapidly.

More companies in RNA Therapeutics (non-mRNA) →More companies in Italy →